![]() |
Name |
Penicibrocazine A
|
Molecular Formula | C19H24N2O6S | |
IUPAC Name* |
(1R,4S,5S,9S,11S,14S,15S,19R)-5,15-dihydroxy-1-methylsulfanyl-3,13-diazapentacyclo[11.7.0.03,11.04,9.014,19]icosane-2,8,12,18-tetrone
|
|
SMILES |
CS[C@@]12C[C@@H]3[C@H](N1C(=O)[C@@H]4C[C@H]5[C@H](N4C2=O)[C@H](CCC5=O)O)[C@H](CCC3=O)O
|
|
InChI |
InChI=1S/C19H24N2O6S/c1-28-19-7-9-12(23)3-5-14(25)16(9)21(19)17(26)10-6-8-11(22)2-4-13(24)15(8)20(10)18(19)27/h8-10,13-16,24-25H,2-7H2,1H3/t8-,9+,10+,13+,14+,15+,16+,19-/m1/s1
|
|
InChIKey |
FVIIUOKQRWILTI-YHDCQKTBSA-N
|
|
Synonyms |
Penicibrocazine A
|
|
CAS | NA | |
PubChem CID | 139585942 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 408.5 | ALogp: | -1.5 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 141.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 28 | QED Weighted: | 0.616 |
Caco-2 Permeability: | -4.938 | MDCK Permeability: | 0.00001140 |
Pgp-inhibitor: | 0.048 | Pgp-substrate: | 0.195 |
Human Intestinal Absorption (HIA): | 0.594 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.101 |
Blood-Brain-Barrier Penetration (BBB): | 0.02 | Plasma Protein Binding (PPB): | 41.28% |
Volume Distribution (VD): | 0.455 | Fu: | 60.94% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.103 |
CYP2C19-inhibitor: | 0.018 | CYP2C19-substrate: | 0.375 |
CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.179 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.074 |
CYP3A4-inhibitor: | 0.019 | CYP3A4-substrate: | 0.951 |
Clearance (CL): | 7.932 | Half-life (T1/2): | 0.929 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.55 |
Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.797 | Maximum Recommended Daily Dose: | 0.912 |
Skin Sensitization: | 0.338 | Carcinogencity: | 0.743 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.02 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003671 | ![]() |
0.674 | D0I1LH | ![]() |
0.231 | ||
ENC002661 | ![]() |
0.674 | D04SFH | ![]() |
0.229 | ||
ENC003617 | ![]() |
0.583 | D0Z1FX | ![]() |
0.225 | ||
ENC003596 | ![]() |
0.514 | D00YWP | ![]() |
0.218 | ||
ENC003809 | ![]() |
0.281 | D0IX6I | ![]() |
0.213 | ||
ENC003573 | ![]() |
0.272 | D0KR5B | ![]() |
0.213 | ||
ENC004418 | ![]() |
0.254 | D0Z4ZT | ![]() |
0.213 | ||
ENC005146 | ![]() |
0.246 | D0T0LU | ![]() |
0.208 | ||
ENC005140 | ![]() |
0.246 | D00ZFP | ![]() |
0.207 | ||
ENC005142 | ![]() |
0.242 | D0H4JM | ![]() |
0.206 |